Fig. 3: PPX cotreatment ameliorated striatal astrocytic NLRP3 inflammasome activation in mice. | Acta Pharmacologica Sinica

Fig. 3: PPX cotreatment ameliorated striatal astrocytic NLRP3 inflammasome activation in mice.

From: Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson’s disease

Fig. 3

a–e Western blots (a, b) and group data of cleaved IL-1β (c), ASC (d), and cleaved Casp-1 (e) protein levels in the striatum, n = 3. f–i Representative images (f) showing NLRP3+ (green) and GFAP+ (red) fluorescent signals, scale bar is 50 μm. Quantification for NLRP3+ (g, n = 4) and GFAP+ (h, n = 4) intensities and the percentage of NLRP3+GFAP+ over GFAP+ cells (i, n = 4), assessed by ImageJ software. One-way ANOVA followed by Tukey’s post hoc analysis. Mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. as indicated. Casp-1 caspase-1.

Back to article page